688076 Jiangsu Sinopep-Allsino Biopharmaceutical
- 51.82
- -0.10-0.19%
Jiangsu Sinopep-Allsino Biopharmaceutical News
Nootech Biotech (688076): The performance slightly exceeded our expectations, and the gross margin further increased the continuous release of peptide APIs
Nootech Biotech (688076): Rapid growth in the third quarter, commercial orders+new production capacity can be expected in the future
Nootech Biotech (688076): Performance is in line with expectations, and the same high growth is expected to continue throughout the year, with the same high growth rate as in peptides
Nootech Biotech (688076): In-depth layout of the peptide field ushered in the harvest period with the GLP-1 wave
Nootech Biotech (688076): Performance is in line with expectations, independent selection and customized production go hand in hand
Nootech Biotech (688076): Peptide advantages continue to expand, and performance significantly exceeds expectations
Nootech Biotech (688076): Performance continues to grow at a high rate, and new production capacity of 10-ton peptides is expected to be implemented ahead of schedule
Nootech Biotech (688076): More optimistic about the sustainability of “sharp rise in volume and price” driven by peptides
Nootech Biotech (688076): High performance growth, gradual expansion of the “time+technology” leading edge
Nootech Biotech (688076): Peptide production capacity and orders soared, 1H24 net profit increased 7 times
Nootech Biotech (688076): International BD continues to drive high quality production capacity leading layout
Nootech Biotech (688076): Performance exceeds forecast, multiple strategic partnerships with the center have been implemented, production capacity release is accelerating, and high growth is expected to continue
Nootech Biotech (688076): Two-wheel drive is booming, 2024H1 performance growth is in line with expectations
CICC Starts Jiangsu Sinopep-Allsino Biopharmaceutical at Outperform With 88 Yuan Price Target
Nootech Biotech (688076): Deep-cultivating peptides to take advantage
Nootech Biotech (688076): Deeply involved in the peptide industry for many years, ushered in a harvest period, accelerated development under GLP-1 catalysis
Nootech Biotech (688076): The GLP-1 industry chain took the lead in benefiting from several tons of production capacity to help it take off
Nootech Biotech (688076): 2024 semi-annual results forecast released, profits continue to explode, surpassing market expectations
Nootech Biotech (688076): Self-selected products continue to be released, 24H1 performance grows rapidly
Nootech Biotech (688076): Performance exceeds expectations, continues to achieve advantages in the field of peptides, and the trend of high growth continues
No Data
